Ardelyx, Inc. (NASDAQ:ARDX) Stock Has Average Target Price of $13.90 According to Brokerages

Shares of Ardelyx, Inc. (NASDAQ:ARDX) have been assigned an average rating of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $13.90.

Several research analysts recently issued reports on ARDX shares. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Ardelyx in a research report on Friday, August 7th. BTIG Research decreased their price objective on Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, August 7th. TD Cowen lowered their price objective on Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ardelyx in a research note on Friday, September 25th. Finally, Piper Sandler dropped their target price on Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Monday, August 17th.

Insiders Place Their Bets

In related news, insider Mike Kelliher sold 7,758 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $29,945.88. Following the sale, the insider owned 349,660 shares of the company’s stock, valued at $1,349,687.60. The trade was a 2.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James Brady sold 15,136 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $58,424.96. Following the completion of the sale, the insider owned 245,930 shares in the company, valued at $949,289.80. This trade represents a 5.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,059 shares of company stock worth $486,588 over the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ARDX. Knott David M Jr acquired a new position in Ardelyx in the first quarter valued at about $1,240,000. AIGH Capital Management LLC bought a new stake in Ardelyx during the second quarter worth about $16,320,000. Rubric Capital Management LP acquired a new stake in shares of Ardelyx during the first quarter worth approximately $11,147,000. Clay Northam Wealth Management LLC acquired a new stake in shares of Ardelyx during the second quarter worth approximately $1,704,000. Finally, BlackRock Inc. acquired a new stake in shares of Ardelyx during the second quarter worth approximately $119,874,000. 58.92% of the stock is owned by institutional investors.

Ardelyx News Summary

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Wedbush maintained an Outperform rating on Ardelyx, although it reduced its price target to $8 from $9. The target still implies substantial upside from recent levels, providing a supportive signal despite the cautious adjustment. Wedbush cuts price target on Ardelyx
• Neutral Sentiment: Ardelyx will report third-quarter 2026 financial results on November 3. Investors will focus on sales of IBSRELA and XPHOZAH, patient starts, payer access issues and management’s outlook for growth. The previous quarter included 34.3% year-over-year revenue growth but an EPS loss that was worse than analysts expected. Ardelyx to report third-quarter 2026 financial results
• Negative Sentiment: Multiple law firms publicized a securities class action covering investors who purchased Ardelyx shares from January 13, 2025 through August 6, 2026. The allegations claim Ardelyx overstated the commercial performance and growth prospects of IBSRELA and XPHOZAH while payer prior-authorization and step-edit restrictions slowed new-patient starts. The lead-plaintiff deadline is November 16, 2026. These are allegations, and the lawsuit could create legal costs, reputational risk and additional uncertainty around the company’s sales outlook. Ardelyx securities class action deadline alert

Ardelyx Price Performance

Shares of ARDX stock opened at $3.21 on Friday. Ardelyx has a 12 month low of $3.05 and a 12 month high of $8.40. The company has a market capitalization of $799.89 million, a P/E ratio of -14.59 and a beta of 0.68. The stock has a 50 day moving average of $3.57 and a two-hundred day moving average of $4.97. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.08) earnings per share. As a group, equities analysts expect that Ardelyx will post -0.20 EPS for the current year.

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s products are designed to act locally in the gastrointestinal tract to address diseases involving phosphate, sodium, and other electrolytes.

Ardelyx’s primary products include XPHOZAH (tenapanor), an oral treatment approved in the United States to reduce intestinal phosphate absorption in adults with chronic kidney disease on dialysis who have hyperphosphatemia, and IBSRELA (tenapanor), an oral therapy approved for the treatment of irritable bowel syndrome with constipation in adults.